New eye drops for dry eye pass safety check in large trial

NCT ID NCT04735393

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested the safety of reproxalap eye drops in 757 adults with dry eye disease. Participants used the drops for up to one year. The main goal was to check for serious side effects like vision changes or eye pressure increases. Results will show whether the drops are safe enough to move forward.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
reproxalap ophthalmic solution (0.25%)
What this could lead to
If it works, this could offer a new eye drop option to ease dry eye symptoms with a good safety profile.
What could go wrong
This is a safety-focused trial, not designed to prove the drops work. Even if safe, reproxalap may not relieve symptoms better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRY EYE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Andover Eye Associates

    Andover, Massachusetts, 01810, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.